Sangamo Therapeutics, Inc.
Sangamo Therapeutics works on the treatment of patients with genomic diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Sangamo Therapeutics' stock with a target price of $3.14, indicating potential growth.
Financial Health
Sangamo Therapeutics has decent revenue and cash flow, but its financial indicators show room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SGMO
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketAge-Reversal Biotech
Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Genome editing focus
Sangamo’s zinc finger platform is a distinctive science play; it can create upside if clinical results succeed, though outcomes are uncertain.
Clinical catalysts ahead
Trial readouts and regulatory moves tend to move the share price significantly; this creates opportunity and volatility.
Partnerships and funding
Collaborations and licensing deals can de‑risk programmes or provide cash, but the company may still need financing, which can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
